Abstract:Objective: To determine how dysfunctional astrocyte glutamate transporters contribute to microglial pruning of glutamatergic synapses and memory deficiency in Alzheimer’s disease (AD). Background: Astrocytes are the most abundant and heterogeneous type of glial cells in the brain, we tested the hypothesis that amyloid fibrils impair astrocyte glutamate transporters, thus leading to an abnormal accumulation of extrasynaptic glutamate, which in turn contributes to microglial pruning of glutamatergic synapses and memory deficiency in the rodent models of AD. Design/Methods: Aβ1–40 fibrils were microinjected bilaterally into hippocampal CA1 areas in rats. In another cohorts, DL-threo-beta-benzyloxyaspartate (DL-TBOA), a specific inhibitor of glutamate transporter 1 (GLT1), or ceftriaxone (used to enhance GLT1 function) were also microinjected into hippocampal CA1 areas. Immunostaining and immunoblotting were performed to detect the expression of GLT1 in astrocytes. Complement C1q production and microglial pruning of glutamatergic synapses were assessed by 3D immunofluorescence imaging. Morris water maze test was performed to evaluate the cognitive function. Results: A significant GLT1 reduction in the hippocampal astrocytes in rats injected with amyloid fibrils, indicating dysfunctional glutamate uptake. Microinjection of ceftriaxone significantly attenuated C1q expression and endocytosis of vGluT1 within microglia, and improved behavioral performance in the modeled rats. These results suggested that upregulation of GluT1 expression restored the synaptic microglial pruning and cognition impaired by amyloid fibrils. Meanwhile, in naive rats, microinjection of DL-TBOA substantially increased C1q expression, increased localization of vGluT1 within microglia, and impaired performance in the Morris water maze. This suggests that dysfunctional GluT1, which likely leads to extracellular accumulation of glutamate, contributes to C1q-mediated microglial pruning of synapses and cognitive deficits induced by amyloid fibrils. Conclusions: Reduction of astrocytic GLT1 contributes to C1q production and microglial pruning of glutamatergic synapses, hippocampal synaptic dysfunction and memory deficit in the AD model. Disclosure: Dr. Wu has nothing to disclose. Dr. Bie has nothing to disclose. Dr. Naguib has nothing to disclose.

Glutamate Transporter 1 as a Novel Negative Regulator of Amyloid β

PS1/gamma-secretase acts as rogue chaperone of glutamate transporter EAAT2/GLT-1 in Alzheimer's disease

Proteome Profiling Identified Amyloid-β Protein Precursor As a Novel Binding Partner and Modulator of VGLUT1.

Astrocytic GluN2A and GluN2B Oppose the Synaptotoxic Effects of Amyloid-β1-40 in Hippocampal Cells.

Genetic Dissection of Glutathione S-transferase Omega-1: Identification of Novel Downstream Targets and Alzheimer’s Disease Pathways

The Downregulation of ITGAX Exacerbates Amyloid-β Plaque Deposition in Alzheimer's Disease by Increasing Polarization of M1 Microglia

Amyloid Fibril–Induced Astrocytic Glutamate Transporter Disruption Contributes to Complement C1q-Mediated Microglial Pruning of Glutamatergic Synapses

GlyT1 Inhibition by NFPS Promotes Neuroprotection in Amyloid-β-Induced Alzheimer's Disease Animal Model

Reduction of Astrocytic Glutamate Transporter Contributes to Amyloid-induced phagocytosis

The role of GLP-1/GIP receptor agonists in Alzheimer's disease

GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration

Aβ-mediated synaptic glutamate dynamics and calcium dynamics in astrocytes associated with Alzheimer's disease

Glutamate: Molecular Mechanisms and Signaling Pathway in Alzheimer's Disease, a Potential Therapeutic Target

Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss

Therapeutic Potential of Neu1 in Alzheimer's Disease Via the Immune System

Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease

Alpha-secretase inhibition impairs Group I metabotropic glutamate receptor-mediated protein synthesis, long-term potentiation and long-term depression

Myeloid Arginase 1 Insufficiency Exacerbates Amyloid-β Associated Neurodegenerative Pathways and Glial Signatures in a Mouse Model of Alzheimer's Disease: A Targeted Transcriptome Analysis

Regulation of neuroinflammation with GLP-1 receptor targeting nanostructures to alleviate Alzheimer’s symptoms in the disease models

Myeloid Arginase 1 Insufficiency Exacerbates Amyloid-β Associated Neurodegenerative Pathways and Glial Signatures in a Mouse Model of Alzheimer’s Disease: A Targeted Transcriptome Analysis

The Association of Circulating Glucagon-Like Peptide-1 with Cognitive Functions and Biomarkers in Alzheimer's Disease